Company profile
Urologix, Inc.
OTC: ULGX · Healthcare · Medical - Devices
#586 of 1,418 Healthcare companies by revenue30th-percentile growth
EA Score
——FH —DQ 27GM —SS 51
v0.1 · 25/100 weight · pillars only
↑ listing tenure, growth stability · ↓ market scale, disclosure history
Methodology →Revenue TTM
$12.2M
Rev growth YoY (TTM)
-19.4%
Net income (FY)
-$7.6M
Employees
61
as of 2026-08-31
Market cap
$2.2k
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$14.2M$14.2M2014
Net income-$7.6M-$7.6M2014
Operating income-$6.9M-$6.9M2014
Total assets$5.7M$5.7M2014
Liabilities$12.6M$12.6M2014
Equity-$7.0M-$7.0M2014
Revenue trend
FY2012 – FY2014 · USD
FY12
FY12
FY12
FY13
FY14
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Urologix, Inc.’s revenue?
Urologix, Inc. booked $14.2M in FY2014 revenue, contracting 14% year over year — slower than 70% of Healthcare companies we track, at a -53.4% net margin.
Peers · Healthcare
VSee Health, Inc.35DLineage Cell Therapeutics, Inc.56CSunniva Inc.——Opus Genetics, Inc.39DArbutus Biopharma Corp61CHealthcare Triangle, Inc.40DNeighbors
Hennepin →Key facts
CEOBryon Merade
SectorHealthcare
IndustryMedical - Devices
HeadquartersMinneapolis, MN
ExchangeOTC: ULGX
Employees61
IPO date1996-05-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.